Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Histo-FACT
NCT07261150Phase 3Not yet recruiting
- Sponsor
- University of Minnesota
- Start
- Dec 2026
- Primary completion
- Dec 2030
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of liposomal amphotericin b and posaconazole in histoplasmosis (6 arms), sponsored by University of Minnesota. Primary endpoints: Mortality at 2 weeks, Mortality at 26 weeks and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
liposomal amphotericin bposaconazole
03
Conditions
histoplasmosis
Beyond the preview
Go deeper on NCT07261150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261150.